Trials / Withdrawn
WithdrawnNCT01832103
The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)
A Phase I Study to Evaluate the Pharmacokinetics of MK-7145 Following Single Dose Administration in Patients With Moderate Renal Insufficiency
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to obtain a preliminary pharmacokinetic profile of MK-7145 2 mg immediate release (IR) following single-dose administration in male participants with moderate renal insufficiency. In addition, the study will evaluate the pharmacodynamic effect of a single dose of MK-7145 2 mg IR on 24-hour net natriuresis in male participants with moderate renal insufficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-7145 |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2013-04-15
- Last updated
- 2013-09-24
Source: ClinicalTrials.gov record NCT01832103. Inclusion in this directory is not an endorsement.